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Background: Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. While current treatment
regimens achieve almost 80% overall survival, long-term side effects of chemotherapeutic agents can be severe.
The functional BCL2-938C > A promoter polymorphism is known to influence the balance between survival and
apoptosis of malignant hematolymphoid cells. We investigated its usefulness as a marker for treatment stratification
for children with ALL.
Methods: We analyzed DNA from 182 children suffering from ALL in this study to determine genotypes of the−938
C > A polymorphism by “slow-down” PCR.
Results: ALL patients with the BCL2-938CC genotype had an approximately 3-fold higher risk of belonging to a
high-risk group. Within the high-risk group, 50% of BCL2-938CC patients were classified as high-risk due to poor
prednisone response whereas only 33% of patients with AC and AA genotypes were classified as high-risk for the
same reason.
Conclusions: Our results suggest that BCL2-938C > A genotyping may be beneficial for therapy response prediction
in ALL patients, and warrant examination in a larger cohort to validate its usefulness for treatment stratification of
pediatric ALL patients.
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Leukemia is the most common pediatric cancer and the
most common cause of disease-related death in child-
hood. Acute lymphoblastic leukemia (ALL) accounts for
80% of pediatric leukemias [1]. The disease is character-
ized by uncontrolled proliferation of lymphoid progeni-
tors in the bone marrow with consequent accumulation
of malignant lymphoblasts in both bone marrow and
peripheral blood. Current treatment regimens result in
approximately 80% overall survival (OS) in children with
ALL. However, the chemotherapeutic agents used target
both malignant and non-malignant cells, and the side ef-
fects can be severe, especially for high-risk patients, who* Correspondence: annette.kuenkele@uk-essen.de
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reproduction in any medium, provided the orreceive the most aggressive therapy [1-3]. Particularly,
long-term side effects are of great interest in pediatric
oncology, since these patients are treated very early in
life, with many years following their disease. The identi-
fication of additional markers which would allow im-
proved risk stratification and more individually tailored
therapy regimens is highly desirable, even to lower risk
of adverse long-term side effects. For the time being the
most important outcome predictors are genetic subsets,
initial white blood cell count, age at diagnosis, and early
treatment response measured by minimal residual dis-
ease (MRD) markers [4]. Although many genetic abnor-
malities are associated with clinical outcome, only few of
them are routinely used for treatment stratification.
These include the presence of trisomy 4, 10 or 17 or the
Philadelphia chromosome. Occasionally the significance
of a given prognostic factor may change with advancesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ALL patients with the Philadelphia chromosome has im-
proved substantially since tyrosine kinase inhibitors were
included in the treatment regimen [5]. Finding markers
for risk stratification can improve risk group assignment
and consequently improve treatment efficacy by applying
as much therapy as needed to cure the patient but
avoiding over-treatment, which can increase long-term
adverse side effects. Bcl-2 was initially identified as an
anti-apoptotic regulatory protein [6], but it also serves as
an inhibitor of proliferation [7]. The functional implica-
tion of Bcl-2 in tumorigenesis is ambiguous, as the
anti-apoptotic effect may be oncogenic while the anti-
proliferative effect appears tumor-suppressive. Which of
the dual functions predominates seems to be tissue spe-
cific. This may explain why the prognostic implication of
Bcl-2 expression depends on cancer type. For example,
its expression is related to decreased survival in chronic
lymphocytic leukemia and prostate cancer [8,9], whereas
increased Bcl-2 expression is associated with favorable
outcome in colorectal and breast cancer [10,11]. Bcl-2
may play a crucial role in the survival of hematolymphoid
cells, where Bcl-2 inhibits apoptosis by preventing
cytochrome c release from the mitochondria, thereby
blocking caspase activation [12]. BCL2 has two pro-
moters with different functional properties. Transcrip-
tion is driven by the P1 promoter, while the P2 promoter
acts as a negative regulatory element [13,14]. Cis alter-
ations have been shown to increase the activity of the P2
promoter, suppressing Bcl-2 expression [14]. The func-
tional−938 C > A promoter polymorphism is located in
the inhibitory P2 promoter region [15]. C and A alleles of
this polymorphism differentially bind transcription fac-
tors and affect promoter activity. The C allele shows al-
tered binding of transcription factors, increased activity
of inhibitory promoter P2 and therefore decreased ex-
pression of Bcl-2. In patients with lymph node-negative
breast cancer, oropharyngeal squamous cell carcinoma,
chronic lymphocytic leukemia, glioblastoma multiforme
and prostate cancer the A allele has been associated with
higher Bcl-2 expression levels and the−938 C > A poly-
morphism has been associated with survival of patients
suffering from these cancers [16-20]. The present study
investigates genotypes of the BCL2−938 C > A promoter
polymorphism as potential markers for risk and treat-
ment stratification in children with ALL.
Methods
Patient cohort
Research followed the tenets of the Declaration of
Helsinki, and was approved by the institutional review
board of Children’s University Hospital Essen. The study
comprised blood samples from 182 patients diag-
nosed with ALL and treated between January 1987and December 2010 in the Department of Pediatric
Hematology-Oncology of the University Hospital Essen
according to the clinical trial protocols ALL-BFM 1990,
1995 and 2000, Interfant, EsPhALL and CoALL for
which informed consent was obtained. Data were retro-
spectively evaluated from medical records.
Determination of BCL2−938C > A genotypes
To determine the BCL2−938 genotypes, DNA was
isolated from peripheral blood by using a com-
mercially available kit according to the manufactur-
er’s instructions (QIAamp, Qiagen, Hilden, Germany).
Genotypes of the−938 C > A polymorphism were deter-
mined by slowdown PCR [21]. Previously described
primers were used for the region of interest: for-
ward primer 5′-CAGCAGCTTTTCGGAAAATG-3′ and
biotinylated reverse primer 5′-TATCCACGGGACCGC
TTCTTCAC-3′ [18]. The 134 bp PCR products were ana-
lyzed by pyrosequencing using the primer 5′-TCCC
CGGCTCCTTCATCGTC-3′ on the PSQ96 system ac-
cording to the manufacturer’s instructions (Biotage,
Uppsala, Sweden), and as previously described [18]. Re-
sultswere analyzed using PSQ96 SNP software (Biotage,
Uppsala, Sweden). Appropriate negative and positive
controls for each genotype were included. Sequencing
accuracy was verified by re-genotyping 60 samples using
pyrosequencing and 10 randomly selected samples by
Sanger sequencing (100% concordance with results
from slowdown PCR). Slowdown PCR and pyro-
sequencing assays have been extensively used and vali-
dated for polymorphism genotyping in previous studies
[16-18].
Statistical analysis
This study used a hypothesis-driven retrospective candi-
date gene approach to investigate the BCL2−938C > A
polymorphism. Kaplan-Meier analyses and the log-rank
test were used to retrospectively evaluate the relation-
ship between risk group, BCL2 genotype and outcome
from the date of primary diagnosis to the end of follow-
up. Multiple Cox regression analyses were performed to
assess the joint impact of BCL2−938C > A genotype, pa-
tient gender and age with or without risk group classifi-
cation on the clinical outcome. Student’s t-test was used
for genotype-dependent comparison of continuous vari-
ables. Contingency tables and Pearson’s chi-squared test
were used to compare categorical variables dependent
on BCL2 genotypes. AA and AC genotypes have been
combined as one group to allow for odds ratio analysis
and linear testing versus risk groups. Deviation from the
Hardy-Weinberg equilibrium was assessed using the
Hardy-Weinberg equilibrium public domain software
by S. Rodriguez et al. [22] (http://www.oege.org/soft-
ware/hwe-mr-calc.shtml). Differences with p < 0.05 were
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ducted using SPSS 17.0 (IBM, Ehningen, Germany), or
GraphPad Prism 4.0 (GraphPad Software Inc., La Jolla,
CA, USA).
Results
We retrospectively genotyped a series of 182 children di-
agnosed and treated for ALL in the Children’s University
Hospital Essen for the BCL2−938C > A polymorphism,
for which the patient characteristics are presented in
Table 1. Mean age of patients at diagnosis was 6.5 (range
0.1-17.7) years. The median follow-up for patients with-
out fatal events was 5.2 years and the median age at
recruiting for follow-up was 11.7 (range 1.2-30.2) years.
Event-free survival (EFS) and 5-year OS of the entire pa-
tient cohort was 71% and 88.5%, respectively. From theTable 1 Clinico-pathological characteristics at primary
diagnosis and genotype distribution
All BCL2−938 genotype P
valueAC / AA CC
n (%) 182 141 (77.5) 41 (22.5)
Mean age (years ± SD) 6.5 ± 4.6 6.3 ± 4.5 7.1 ± 4.6 0.298
Gender (male/female) 111/71 83/58 28/13 0.276
Relapse
no 137 105 (76.7) 32 (23.3) 0.640
yes 45 36 (80.0) 9 (20.0)
HSCT
no 119 97 (81.5) 22 (18.5) 0.073
yes 63 44 (69.9) 19 (30.1)
Relapse after HSCT (n = 63)
no 40 26 (65.0) 14 (35.0) 0.270
yes 23 18 (78.3) 5 (21.7)
Risk Group Classification
standard 67 59 (88.1) 8 (11.9)
medium 72 53 (73.6) 19 (26.4) 0.008
high 43 29 (67.4) 14 (32.6)
Prednisone response (n = 174)
good 160 129 (80.6) 31 (19.4) 0.148
poor 14 9 (64.3) 5 (35.7)
Molecular genetics (n = 176)
no aberration 121 94 (77.7) 27 (22.3) 0.627
BCR/ABL fusion 13 9 (69.2) 4 (30.8)
TEL/AML rearrangement 35 28 (80.0) 7 (20.0)
MLL/AF4 rearrangement 3 3 0
TCF3/PBX1 rearrangement 1 1 0
chromosomal 9 deletion 1 1 0
hyperdiploidity 2 2 0
HSCT, Hematopoietic stem cell transplantation.initial cohort, 29 patients died from relapse (n = 16),
bronchiolitis obliterans and respiratory insufficiency
(n = 1), multiple organ toxicity (n = 6), renal failure
(n = 1), infection (n = 4) or due to unknown causes (n =
1). The initial leukocyte count was between 0 and 20
000 leukocytes/nl for 112 patients, between 20 000 and
100 000 leukocytes/nl for 49 patients, above 100 000
leukocytes/nl for 19 patients and data was unavailable
for 2 patients. Central nervous system involvement was
detected in 6 patients. Molecular genetic abnormalities
are summarized in Table 1. Patient immunophenotyping
confirmed common ALL in 126 patients, early pre-B
ALL in 28 patients, pre-B ALL in 7 patients, pre-T ALL
in 2 patients, an intermediate T-ALL in 12 patients and
a mature T-ALL in 1 patient. Immunohistological diag-
nosis of the ALL subtype was not possible in 6 patients.
In this cohort, 160 patients responded well and 14
responded poorly to prednisone, whereas data were un-
available for 8 patients about prednisone response. The
cohort analyzed here was treated under several different
treatment protocols, including the ALL BFM 2000
protocol (n = 126), the ALL-BFM 1995 protocol (n = 26),
the ALL-BFM 1990 protocol (n = 14), the Interfant
protocol (n = 6), the EsPhALL protocol (n = 6), the
CoALL protocol (n = 4). Of the initial cohort, 45 patients
relapsed, with the median time from diagnosis to relapse
being 2.4 (range 0.2-5.5) years and 63 patients under-
went hematopoietic stem cell transplantation, with the
median time between initial diagnosis of ALL and
hematopoietic stem cell transplantation being 2.1 (range
0.3-9.1) years. Of the patients who underwent
hematopoietic stem cell transplantation 25 relapsed fol-
lowing therapy.
The genotype distribution of the BCL2−938C > A poly-
morphism was representative of healthy Caucasians. It
consisted of n = 41 CC, n = 85 AC and n = 56 AA, which
is in line with the Hardy-Weinberg equilibrium. The fre-
quency of the C allele within this cohort (0.46) did not
significantly differ from published data from healthy
Caucasian cohorts [16,18]. The patient genotype of the
BCL2−938C > A polymorphism was not correlated with
patient outcome or with clinical risk markers, including
prednisone response or identified molecular genetic
anomalies. No difference concerning OS or EFS between
good or poor prednisone responders or between the
identified molecular genetic anomalies was detected
(Data not shown). As expected, risk groups were signifi-
cantly correlated with OS. Patients categorized in
standard-risk groups according to the respective proto-
col had a significantly better OS than the patients cate-
gorized in medium-or high-risk groups (Figure 1A and B).
Carrier status of either the CC or the AC/AA genotype
of the BCL2−938 C > A polymorphism did not sig-
nificantly correlate with either patient EFS or OS
Figure 1 Risk assessment of ALL patients treated within several different trial treatment regimens correlated with patient outcome.
Kaplan-Meier curves are shown for the 182 pediatric ALL patients assessed retrospectively in this study. Patients were treated within ALL BFM
2000, ALL-BFM 1995, ALL-BFM 1990, Interfant, EsPhALL, CoALL and CoALL/BFM. A-B. Patients with a standard risk (SR) ALL have a significant
better EFS and OS than those with a medium (MR) or high risk (HR) ALL. C-D. There is no significant difference concerning EFS or OS between
combined AC/AA genotype and CC genotype of the BCL2−938C > A polymorphism.
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of patients with a CC genotype increases linearly from
the standard–(11.9%), through the medium–(26.4%) and
high-risk groups (32.6%, p = 0.008; Table 1). A child with
a CC genotype has a significantly higher risk to belong to
the medium-or high-risk groups instead of the standard-
risk group (OR = 2.64 [95%CI 1.07-6.54); p = 0.031 and
OR = 3.56 [95%CI 1.34-9.45]; p = 0.008, Table 2).
To further investigate the discrepancy between risk
group assignment and outcome, we performed multi-
variate regression analyses and exploratory analyses of
the high-risk group. Multiple Cox regression analyses
revealed that BCL2−938C > A genotype remained non-
significant for EFS and OS even after correction for dif-
ferent covariables and especially after correction for the
risk group classification (Additional file 1: Table S1).
Poor therapy response as well as genomic aberration of
tumor cells leads to classification of patients as high risk.
Interestingly, 77% of patients with the CC genotype were
classified as high risk due to poor response to therapy,Table 2 BCL2−938C > A genotype and ALL risk groups
BCL2−938 genotype
Risk group CC AC / AA Odds Ratio (95% CI) P value
standard 8 (11.9) 59 (88.1) 1.00
medium 19 (26.4) 53 (73.6) 2.64 (1.07-6.54) 0.031
high 14 (32.6) 29 (67.4) 3.56 (1.34-9.45) 0.008
CI, Confidence Interval.whereas only 55% of patients with the AC/AA genotype.
Poor therapy response is defined by poor response to
prednisone or by detection of MRD at certain time
points during therapy. Remarkably, the putative differ-
ence in therapy response seems to be related to prednis-
one. In high risk patients with available prednisone
response data (n = 37) 50% of the children with the CC
genotype were classified as high-risk because of poor
prednisone response, while only 33% of the AC/AA pa-
tients were classified as high-risk due to poor prednisone
response (Table 3). In conclusion, we here identified the
BCL2-938 CC genotype as a novel risk factor predispos-
ing childhood ALL patients to a higher treatment risk
group, although overall survival was similar to patients
in all risk groups.
Discussion
Treatment of ALL involves some of the most complex
chemotherapy combinations and treatment schedulesTable 3 High Risk patients with available prednisone
response data and BCL2-938C > A genotype
All BCL2-938 genotype
AC / AA CC
n (%) 37 27 (73.0) 10 (27.0)
High risk due to poor prednisone response
no 23 (62.2) 18 (66.7) 5 (50.0)
yes 14 (37.8) 9 (33.3) 5 (50.0)
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motherapy is initially used to reduce the burden of lym-
phoblasts in the bone marrow and restore normal
hematopoietic function. Consolidation therapy is then
used with the intention of clearing all drug-resistant
leukemia cells that have survived induction therapy from
the blood and bone marrow and to prevent minimal re-
sidual disease. Maintenance chemotherapy consists of
two to three years of low-dose antineoplastic drugs
designed to prevent leukemia relapse during the crucial
few years after remission, induction and consolidation.
The significant improvements in survival for children
with ALL during the past two decades can be attributed
to both favorable disease biology and the success of care-
fully designed, risk-adapted treatment. Risk stratification
evolved during these decades to incorporate response to
initial treatment, cytogenetics and other biological char-
acteristics of the disease. Measurement of minimal re-
sidual disease is now used to improve risk stratification
and to allocate patients to hematopoetic stem cell trans-
plantation in many pediatric clinical trials.
In this study, we examined the BCL2−938 C > A poly-
morphism as possible marker for risk stratification and
predicting outcome in pediatric ALL patients. The long
follow-up time of more than 60 months allowed the
evaluation of OS and EFS. Both were comparable to that
reported for other cohorts of pediatric ALL patients with
similar follow-up periods [23-25]. Since pediatric cancers
are relatively rare, only those treatment centers seeing a
large proportion of children with cancer are able to re-
cruit sufficient numbers of patients for retrospective ana-
lyses of long-term follow-up events, and this takes a long
time to be accomplished. The patients analyzed in our
study were treated according to seven different protocols.
The variety in the protocols stem from changes of trial
protocols made during the long recruitment times
and age-adjusted treatment regimens. This permanent
change and development can complicate analyses and
comparability of analyses, in addition to the small num-
bers of patients in subgroups with specific molecular
genetics backgrounds or ALL immunophenotyping. Some
limitations exist for the interpretation of the data in this
study, since patients were non-uniformly treated and some
results were detected in (exploratory) subgroup analysis, in
which some subgroups contained small number of patients.
The effect of theBCL2−938C > Apromoter polymorphism
should be assessed in a larger independent cohort of, opti-
mally, uniformly treated patients.
The patient genotype of the BCL2−938C > A poly-
morphism was significantly correlated with risk stratifi-
cation, but not with outcome or the clinical risk markers
examined. As expected, risk groups were significantly
correlated with OS and EFS, so that patients belonging
to the low-risk groups had a significantly better outcomethan the patients belonging to the medium-or high-risk
groups [26,27]. This supports that patients belonging to a
higher risk group require a more intensive treatment
regimen. Since more intensive treatment regimens can
cause severe side effects and/or long-term adverse af-
fects, additional markers to improve selection of the best
treatment regimen have the power to reduce both short-
and long-term adverse patient effects. Bcl-2 is known to
be a possible indicator for therapy response during in-
duction chemotherapy treatment of adult patients with
ALL [28], and Bcl-2 inhibition in combination with
methadone increases the induction of apoptosis in
pediatric ALL cells [29]. In our study, the−938 C > A
BCL2 promoter polymorphism did not correlate with OS
or EFS and is on its own not predictive of outcome of
pediatric ALL patients, but we detected an influence of
the BCL2−938 C > A polymorphism on risk stratification.
In our cohort, the risk of a child with a CC genotype to
be in a specific risk group increased significantly and
linearly from the standard-to high-risk groups, and vice
versa, decreased linearly for patients with either AA or
AC genotypes. In an exploratory analysis, poor therapy
response, and especially response to prednisone was the
main reason for classification of BCL2−938 CC patients
into the high-risk group, although their overall outcome
was not worse than the outcome of patients belonging to
standard-or medium-risk groups. Since it is known that
prednisone treatment decreases Bcl-2 expression and
ALL patients are routinely treated with prednisone, this
polymorphism should be assessed in ALL patients [30].
Furthermore, Bcl-2 is an interesting drug target with dif-
ferent inhibitors under evaluation and the polymorphism
identified here would be an interesting candidate to in-
vestigate its putative biomarker properties [31,32].
Conclusion
Our results suggest that BCL2−938 C > A genotyping
may be beneficial for predicting therapy response in
ALL patients. This polymorphism should be examined
in a larger independent (prospective) cohort to verify the
connection between risk and genotype and validate its
usefulness for treatment stratification of pediatric ALL
patients with regard to its possible interaction with pred-
nisone response.
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